Werner Koopman, theme Metabolic Diseases, received 250K Euro as a member of the CureMILS consortium. The latter is funded by the European Joint Programme on Rare Diseases (EJP-RD), which brings together over 130 institutions from 35 countries and focuses on pre-clinical research to develop effective therapies for rare diseases.
The project will run for three years, receiving a total of 2.4 million Euro in funding, and will apply a cell-based reprogramming strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh Syndrome.
CureMILS involves eight academic partners from Germany (Heinrich Heine University, Duesseldorf; Fraunhofer IME, Hamburg), Austria (Innsbruck University), The Netherlands (Radboudumc), Finland (University of Helsinki), Poland (Institute of Genetics and Animal Biotechnology, Jastrzebiec), Italy (Verona University) and Luxemburg (University of Luxembourg). Other participants include various collaborators (Germany, Austria and Italy) and a patient organization (International Mito Patients; IMP).
At Radboudumc, CureMILS will be carried out in a collaborative effort between the groups of Werner Koopman and Nael Nadif Kasri.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Radboud Young Academy safeguards the future of science
21 January 2021New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.
read more
Increase radio- and immunotherapy efficacy by targeting hypoxia
21 January 2021In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.
read more
Radiation boost lowers risk of prostate cancer recurrence
21 January 2021An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.
read more
New research through grants for Radboudumc researchers
14 January 2021Several researchers at the Radboudumc have received grants to start new studies, including on rare diseases, liver disease and cancer metastases. These are grants from the Dutch Research Council, European Joint Programme on Rare Diseases and the Gastric Liver Disease Foundation.
read more
Should we prepare for a corona-related depression wave? Indira Tendolkar and Eric Ruhé talk about their research projects
13 January 2021Since the outbreak of the SARS-CoV-2, many of us have been staying at home in order to limit our social interactions, to keep ourselves and others safe from the virus. Yet, there’s also concern about what social distancing and anxiety generated by media reports are doing to people's mental health.
read more
RIMLS online award ceremony proudly presenting the winners
13 January 2021In this special webinar of the RIMLS New Year Celebration, scientific director René Bindels reviewed 2020 and looked forward to 2021. But more importantly a number of researchers received prizes in the traditional RIMLS awards ceremony.
read more